Antibody humanization is the process of modifying a non-human antibody, typically from model species such as mice, to make its structure and function more compatible with the human immune system. This involves altering specific regions of the antibody, primarily the framework regions, while preserving the antigen-binding sites. In drug development, humanization enhances the safety profile of a therapeutic antibody by reducing the risk of adverse immune reactions. Thus , the FDA and other regulatory agencies require non-human antibodies to be humanized before they can be tested in humans.

Large Language Models (LLM) offer an innovative computational approach to antibody humanization, providing a powerful alternative to traditional experimental methods. By analyzing vast datasets of antibody sequences, structures, and human immune system interactions, LLMs can predict which amino acid changes will humanize an antibody while retaining its efficacy and reducing immunogenicity. This approach drastically reduces the need for labor-intensive screening and iterative testing, which can take months. LLMs can perform these predictions in a fraction of the time, accelerating the preclinical development process and cutting costs significantly.

At Converge Bio, antibody humanization is one the GenAI-powered solutions we offer. Contact us to learn more about our approach to antibody humanization.